Literature DB >> 3738427

Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA).

M J Pippard, M J Jackson, K Hoffman, M Petrou, C B Modell.   

Abstract

The iron chelating ability and potential toxicity of subcutaneous infusions of the calcium and zinc salts of diethylene triamine penta-acetic acid (DTPA) have been assessed in metabolic balance studies in 2 iron-loaded thalassaemic patients. Infusions of calcium DTPA were locally well tolerated and the drug was as effective as desferrioxamine in mobilising iron. However, daily infusions in the 1st patient also produced symptomatic zinc depletion which could not be controlled by simultaneous oral zinc supplements. Zinc DTPA proved ineffective as an iron chelator, but zinc balance could be maintained in the 2nd patient by combining intermittent (every 4 d) use of calcium DTPA with oral zinc supplements. Combined studies with desferrioxamine and calcium DTPA showed the drugs to have additive effects, probably as a result of the chelation of iron from different body sites.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3738427     DOI: 10.1111/j.1600-0609.1986.tb02282.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  11 in total

Review 1.  World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

Authors:  Christina N Kontoghiorghe; Nicholas Andreou; Katerina Constantinou; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2014-09-26

2.  Comparative acute and chronic toxicity of diethylenetriamine pentaacetic acid (DTPA) and ferric-complexed DTPA to Daphnia carinata.

Authors:  R A van Dam; M J Barry; J T Ahokas; D A Holdway
Journal:  Arch Environ Contam Toxicol       Date:  1996-11       Impact factor: 2.804

3.  Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.

Authors:  F N al-Refaie; B Wonke; D G Wickens; Y Aydinok; A Fielding; A V Hoffbrand
Journal:  J Clin Pathol       Date:  1994-07       Impact factor: 3.411

4.  Desferrithiocin analogue uranium decorporation agents.

Authors:  Raymond J Bergeron; Jan Wiegand; Shailendra Singh
Journal:  Int J Radiat Biol       Date:  2009-04       Impact factor: 2.694

5.  Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA.

Authors:  B Wonke; A V Hoffbrand; M Aldouri; D Wickens; D Flynn; M Stearns; P Warner
Journal:  Arch Dis Child       Date:  1989-01       Impact factor: 3.791

Review 6.  Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.

Authors:  G J Kontoghiorghes
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

Review 7.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

8.  Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.

Authors:  G J Kontoghiorghes; M A Aldouri; A V Hoffbrand; J Barr; B Wonke; T Kourouclaris; L Sheppard
Journal:  Br Med J (Clin Res Ed)       Date:  1987-12-12

Review 9.  The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia.

Authors:  George J Kontoghiorghes; Marios Kleanthous; Christina N Kontoghiorghe
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-01-01       Impact factor: 2.576

10.  Major role of iron uptake systems in the intrinsic extra-intestinal virulence of the genus Escherichia revealed by a genome-wide association study.

Authors:  Marco Galardini; Olivier Clermont; Alexandra Baron; Bede Busby; Sara Dion; Sören Schubert; Pedro Beltrao; Erick Denamur
Journal:  PLoS Genet       Date:  2020-10-28       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.